drugset / Trial / NCT04818632
AZD9833 China PK Study
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer
Timeline
- Start
- 2021-11-12
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camizestrant | Other / unclassified | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Palbociclib | Small molecule | — | — |